- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
SMC ‘U-turn’ offers lifeline to Scottish skin cancer patients
8 August 2016 • Author: Bristol-Myers Squibb
The SMC initially refused access to nivolumab for Scottish patients, opposing the view of the National Institute for Health and Care Excellence (NICE), which approved it to treat patients in England and Wales. However, following a review of additional evidence, the SMC decision has been reversed, bringing access in Scotland on par with the rest of the UK.
The supporting Phase III trials
The decision from the SMC is based on two pivotal Phase III trials (Checkmate -066 and -067). Data from Checkmate -066 have shown significantly more previously-untreated BRAF wild-type patients who received nivolumab were still alive at one year (72.9%) [n=210 95% CI, 65.5-78.9], compared to those treated with the chemotherapy dacarbazine (42.1%) [n=208 95% CI, 33.0-50.9].
Comparison with ipilimumab
Furthermore, in study Checkmate -067 patients with previously untreated advanced melanoma, median progression-free survival was 6.9 months for those treated with nivolumab [n=313 95% CI, 4.3-9.5] compared to 2.9 months in those receiving ipilimumab [n= 311 95% CI, 2.8-3.4].[vi]
Data has shown that previously-untreated patients who received nivolumab experienced fewer serious (grade 3-4) treatment-related adverse events compared to chemotherapy (13% of patients treated with nivolumab [27/206] vs. 17% of those treated with chemotherapy [35/205]).
Nivolumab works by harnessing the ability of the immune system to fight advanced (metastatic or unresectable) skin cancer. It has been shown to significantly improve survival in this disease compared to chemotherapy, regardless of whether a patient has received prior treatment or not.
Once advanced to a stage where it cannot be surgically removed because it has spread to other parts of the body (known as unresectable or metastatic), melanoma can be fatal. It is the most dangerous form of skin cancer, causing more deaths than any other form of the disease.
Rise of melanoma in Scotland
The incidence of melanoma in Scotland has risen by 30% over the last 10 years – a rate higher than any other common cancer, including the country’s biggest cancer killer, lung cancer.
In Scotland, there were around 1,200 people diagnosed with melanoma in 2013 and around 200 died from the disease.
“Until today, we have seen an untenable situation where patients in England and Wales had access to this medicine, while those in Scotland did not”, said Gillian Nuttall, Founder, Melanoma UK. “I am delighted that today’s decision will bring new hope for patients who have been waiting for access to this medicine. To prevent this type of disparity continuing to affect patients in future, it is important that we work towards implementation of a more equitable medicines review process across the UK.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics